Literature DB >> 29936665

Validation of a novel Montreal Cognitive Assessment scoring algorithm in non-demented Parkinson's disease patients.

Patricia Sulzer1,2, Sara Becker1,2, Walter Maetzler2,3, Elke Kalbe4, Luc van Nueten5, Maarten Timmers5,6, Gerrit Machetanz1,2, Johannes Streffer5,6, Giacomo Salvadore7, Erich Scholz8, Zuzanna Tkaczynska1,2, Kathrin Brockmann1,2, Daniela Berg2,3, Inga Liepelt-Scarfone9,10,11.   

Abstract

INTRODUCTION: The early diagnosis of mild cognitive impairment (PD-MCI) in Parkinson's disease (PD) is essential as it increases the future risk for PD dementia (PDD). Recently, a novel weighting algorithm for the Montreal Cognitive Assessment (MoCA) subtests has been reported, to best discriminate between those with and without cognitive impairment in PD. The aim of our study was to validate this scoring algorithm in a large sample of non-demented PD patients, hypothesizing that the weighted MoCA would have a higher diagnostic accuracy for PD-MCI than the original MoCA.
METHODS: In 202 non-demented PD patients, we evaluated cognitive status, clinical and demographic data, as well as the MoCA with a weighted and unweighted score. Receiver operating characteristic (ROC) curve analysis was used to evaluate discriminative ability of the MoCA. Group comparisons and ROC analysis were performed for PD-MCI classifications with a cut-off ≤ 1, 1.5, and 2 standard deviation (SD) below appropriate norms.
RESULTS: PD-MCI patients scored lower on the weighted than the original MoCA version (p < 0.001) compared to PD patients with normal cognitive function. Areas under the curve only differed significantly for the 2 SD cut-off, leading to an increased sensitivity of the weighted MoCA score (72.9% vs. 70.5%) and specificity compared to the original version (79.0% vs. 65.4%).
CONCLUSIONS: Our results indicate better discriminant power for the weighted MoCA compared to the original for more advanced stages of PD-MCI (2 SD cut-off). Future studies are needed to evaluate the predictive value of the weighted MoCA for PDD.

Entities:  

Keywords:  Cognition; MoCA; Parkinson’s disease; Screening assessment

Mesh:

Year:  2018        PMID: 29936665     DOI: 10.1007/s00415-018-8942-4

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  27 in total

1.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

2.  The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment.

Authors:  Ziad S Nasreddine; Natalie A Phillips; Valérie Bédirian; Simon Charbonneau; Victor Whitehead; Isabelle Collin; Jeffrey L Cummings; Howard Chertkow
Journal:  J Am Geriatr Soc       Date:  2005-04       Impact factor: 5.562

3.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

4.  Montreal cognitive assessment performance in patients with Parkinson's disease with "normal" global cognition according to mini-mental state examination score.

Authors:  Sarra Nazem; Andrew D Siderowf; John E Duda; Tom Ten Have; Amy Colcher; Stacy S Horn; Paul J Moberg; Jayne R Wilkinson; Howard I Hurtig; Matthew B Stern; Daniel Weintraub
Journal:  J Am Geriatr Soc       Date:  2008-12-10       Impact factor: 5.562

Review 5.  A systematic review of prevalence studies of depression in Parkinson's disease.

Authors:  Jennifer S A M Reijnders; Uwe Ehrt; Wim E J Weber; Dag Aarsland; Albert F G Leentjens
Journal:  Mov Disord       Date:  2008-01-30       Impact factor: 10.338

Review 6.  Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force.

Authors:  Bruno Dubois; David Burn; Christopher Goetz; Dag Aarsland; Richard G Brown; Gerald A Broe; Dennis Dickson; Charles Duyckaerts; Jefferey Cummings; Serge Gauthier; Amos Korczyn; Andrew Lees; Richard Levy; Irene Litvan; Yoshikuni Mizuno; Ian G McKeith; C Warren Olanow; Werner Poewe; Cristina Sampaio; Eduardo Tolosa; Murat Emre
Journal:  Mov Disord       Date:  2007-12       Impact factor: 10.338

7.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease.

Authors:  J C Morris; A Heyman; R C Mohs; J P Hughes; G van Belle; G Fillenbaum; E D Mellits; C Clark
Journal:  Neurology       Date:  1989-09       Impact factor: 9.910

8.  The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years.

Authors:  Mariese A Hely; Wayne G J Reid; Michael A Adena; Glenda M Halliday; John G L Morris
Journal:  Mov Disord       Date:  2008-04-30       Impact factor: 10.338

9.  Screening for Cognitive Impairment in Parkinson's Disease: Improving the Diagnostic Utility of the MoCA through Subtest Weighting.

Authors:  Sophie Fengler; Josef Kessler; Lars Timmermann; Alexandra Zapf; Saskia Elben; Lars Wojtecki; Oliver Tucha; Elke Kalbe
Journal:  PLoS One       Date:  2016-07-20       Impact factor: 3.240

10.  Stability of mild cognitive impairment in newly diagnosed Parkinson's disease.

Authors:  Rachael A Lawson; Alison J Yarnall; Gordon W Duncan; David P Breen; Tien K Khoo; Caroline H Williams-Gray; Roger A Barker; David J Burn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2017-03-01       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.